Published summary: 2026-03-07
Where the evidence converges
National survey of 46,499 workers found a clear dose-response: mild CUD increased work-skipping 1
Moderate evidence · 4 studies
Based on limited number of strong-evidence studies.
ACOEM guideline found no quality evidence supporting cannabis for common work-related pain conditions and recommended against use in safety-sensitive positions
Moderate evidence · 4 studies
Based on limited number of strong-evidence studies.
Where questions remain
Study found cannabis users had lower alertness and slower cognition in work-related testing but did not report more workplace errors, with effects showing "hangover" and fatigue-related patterns
Moderate evidence · 6 studies
Self-reported workplace errors may not accurately capture actual performance differences. Cannabis use patterns were not precisely controlled or verified. The sample size is not specified in the abstr
National survey data showed drug-free workplace policies and EAPs were each associated with 15% lower odds of marijuana use and prescription drug misuse in young workers
Moderate evidence · 6 studies
Cross-sectional design cannot establish causation. People who choose workplaces with drug policies may differ from those who do not. Self-reported drug use and policy awareness. Data from 2004-2008 pr
Review of THC detection methods across blood, urine, saliva, and hair highlights growing challenges for drug testing programs as legal medical cannabis products like Sativex produce positive results
Moderate evidence · 6 studies
Technical review focused on analytical methods rather than policy solutions. Cannot fully resolve the medical vs. recreational use distinction. Inter-individual metabolic variation complicates interpr
Analysis of employed Americans found medical and recreational cannabis users were more similar than different after controlling for health factors, except medical users were more concentrated in construction and mining
Moderate evidence · 6 studies
Cross-sectional survey data. Self-reported cannabis use and medical status. NSDUH definitions of medical use may not match state-specific legal definitions. Cannot determine whether industry differenc
Research gaps
- Only 1 randomized controlled trials exist out of 31 studies — most evidence is observational or from reviews.
- No meta-analyses have been published on this specific topic, limiting the ability to draw pooled quantitative conclusions.
- Sex-specific differences in this area remain understudied.
Key studies
How Long Cannabis Shows Up in Urine — and Why Current Thresholds May Be Wrong
Urine testing is the most common form of cannabis detection in workplaces, criminal justice, and sport — affecting millions of people. This systematic review demonstrates that current thresholds often detect past use rather than recent consumption or impairment. For regular users trying to quit, wee
Occupational medicine guideline says cannabis is not recommended for common workplace injuries and conditions
As legalization expands, employers face pressure to allow cannabis. This provides evidence-based grounds for workplace policies, particularly for safety-sensitive positions.
Oral cannabis produced higher urine drug test concentrations than vaporized cannabis
With vaping and edibles now common methods of cannabis consumption, understanding how different administration routes affect drug testing has direct implications for workplace testing policies and legal proceedings.
Legal CBD Products With Trace THC Can Cause Positive Drug Tests in Oral Fluid
Millions of people use legal CBD products that may contain small amounts of THC. This study proves these products can trigger positive workplace drug tests, potentially costing people their jobs even when they've only used legal, non-intoxicating products.
Cannabis Use and Cannabis Use Disorder Linked to More Missed Work Days in National Survey
With 15.9% of full-time US workers using cannabis in the past month and 6.5% meeting CUD criteria, the workplace impact is substantial. The dose-response relationship between CUD severity and absenteeism provides concrete data for employers and policymakers grappling with cannabis in the workplace p
A Clinical Framework for Assessing Cannabis Impairment Risk in Patients
As medical cannabis use grows, clinicians lack practical tools to evaluate impairment risk. This framework fills a gap between prescribing cannabis and ensuring patients can safely work and drive.
How the research developed
2000–2009
3 studies published. Predominantly observational and review studies.
2010–2014
2 studies published. Predominantly observational and review studies.
2015–2019
4 studies published. Predominantly observational and review studies.
2020–present
22 studies published. Includes 1 RCTs, 4 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 31 peer-reviewed studies: 1 randomized controlled trials (3%), 17 observational studies (55%), 9 reviews (29%), 4 other study types (13%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.